Dr Reddy's Laboratories shares gain on generic Zenatane launch

Shares in Dr Reddy's Laboratories Ltd gain 2.1 percent after the company on Thursday said in a statement that it launched Zenatane, a generic version of Accutane drug, following its approval by the United States Food & Drug Administration (USFDA).

* The company added that the drug had $309 million in sales for the most recent twelve months ending January 2013, according to IMS Health.

* "Assuming an incremental 20-25 percent price drop and 20 percent market share, this could be $50 million per year revenue opportunity for Dr.Reddy's," Morgan Stanley said in a report.

Please read our terms of use before posting comments
TERMS OF USE: The views expressed in comments published on indianexpress.com are those of the comment writer's alone. They do not represent the views or opinions of The Indian Express Group or its staff. Comments are automatically posted live; however, indianexpress.com reserves the right to take it down at any time. We also reserve the right not to publish comments that are abusive, obscene, inflammatory, derogatory or defamatory.